NeOnc Technologies schedules FDA end-of-Phase 1 meeting for brain cancer drug NEO212
NTHI•NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026. The company said Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients and that FDA feedback will guide a revised Phase 2 plan; accelerated approval is not assured.
1. FDA meeting scheduled
NeOnc Technologies scheduled an in-person FDA End-of-Phase 1 meeting for NEO212 on Nov. 17, 2026. The company said previously reported Phase 1 results showed durable disease control in two heavily pretreated brain cancer patients, and management described the outcome as supportive of advancing the drug into Phase 2 and pursuing a registrational strategy. FDA feedback will guide a revised Phase 2 plan, including its patient population and endpoints, with no assurance of accelerated approval.
